FDG PET and alternative imaging in the management of thyroid carcinoma

Nuclear Medicine Review

Volumn 6, Issue 2, 2003, Pages 139-145

  Al Nahhas, Adil M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

131I; 18F FDG PET; 201TI; 99m Tc tetrofosmine; 99mTc MIBI; Differentiated carcinoma of the thyroid; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; ISOTRETINOIN; MEDRONATE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; TETROFOSMIN TC 99M; THYROGLOBULIN; THYROXINE;

CANCER RADIOTHERAPY; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FOLLOW UP; HORMONE INHIBITION; HORMONE SUBSTITUTION; HUMAN; IMAGE ANALYSIS; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN DETERMINATION; RECURRENT DISEASE; REVIEW; SAFETY; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROIDECTOMY; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE MANAGEMENT; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 0842301436     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999; 22, Suppl 11: 3-7.
2. Teppo L, Hakulinen T, Eurocare Working Group. Variation in survival of adult patients with thyroid cancer in Europe. Eur J Cancer 1998; 34: 2238-2252.
3. Pat Kindall-Taylor. Managing differentiated thyroid cancer. BMJ 2002; 324: 988-989.
4. Grant S, Luttrell B, Reeve T, Wiseman J, Wilmshurst E, Stiel J et al. Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer 1984; 54: 1625-1628.
5. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40: 993-994.
6. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003; 88: 3069-3074.
7. Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988; 61: 976-981.
8. Maheshwari YK, Hill CS Jr, Haynie TP 3rd, Hickey RC, Samaan NA. 131I therapy in differentiated thyroid carcinoma: M.D. Anderson Hospital experience. Cancer 1981; 47: 664-671.
9. Ronga G, Fiorentino A, Paserio E, Signore A, Todino V, Tummarello MA et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990; 31: 1766-1771.
10. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee IDS, Jang JJ et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001; 28: 639-645.
11. Waxman A.D, Ramanna L, Chapman N et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981; 22: 861-865.
12. Sutter CW, Masilungan BG, Stadalink RC. False-positive results of I-131 whole-body scans in patients with thyroid cancer. Semin Nucl Med 1995; 25: 279-282.
13. Simon D, Korber C, Krausch M et al. Clinical impact of retenoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002; 29: 775-782.
14. Robbins RJ, Tuttle RM, Sharaf RN et al. Preparation by recombinant human thyrotropin or thyroid hormon withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 619-625.
15. Weightman DR, Mallick UK, Fenwick JD Perros P. Discordant serum Thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up. Cancer 2003; 98: 41-47.
16. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291-2302.
17. Krishna L, Dadparvar S, Brady LW, Micaily B, Meihofer M, Slizofski WJ et al. Paradoxical changes in iodine-131 scintigraphic findings in advanced follicular thyroid cancer. J Nucl Med 1993; 34: 1574-1576.
18. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001; 11: 1169-1175.
19. Hindie E, Melliere D, Lang F et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003; 30: 974-981.
20. Clark OH, Hoelting T. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 1994, 4; 501-505.
21. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80: 1485-1487.
22. Oyen WJ, Verhagen C, Saris E, van den Broek WJ, Pieters GF, Corsten FH. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal. J Nucl Med 2000; 41: 643-646.
23. Piers DA, Sluiter WJ, Willemse PH, Doorenbos H. Scintigraphy with 201TI for detection of thyroid cancer metastases. Eur J Nucl Med 1982; 7 (11): 515-517.
24. Almeida-Filho P, Ravizzini GC, Almeida C, Borges-Neto S. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. Clin Nucl Med 2000; 25: 443-446.
25. Rubella D, Mazzaratta R, Casara D. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 2000; 27: 431-440.
26. Ng DC, Sundram FX, Sin AE. 99mTc-sestamibi and 1311 whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J Nucl Med 2000; 41: 631-635.
27. Alam MS, Kasagi K, Misaki T, Miyamoto S, Iwata M, Iida Y, Konishi J. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation. Thyroid 1998; 8: 1091-1100.
28. Seabold JE, Gurll N, Schurrer ME, Aktay R, Kirchner PT. Comparison of 99mTc-methoxyisobutyl isonitrile and 201TI scintigraphy for detection of residual thyroid cancer after 131I ablative therapy. J Nucl Med 1999; 40: 1434-1440.
29. Nishiyama Y, Yamamoto Y, Ono Y et al. Comparison of 99Tcm-tetrofosmin with 201TI and 131I in the detection of differentiated thyroid cancer metastases. Nucl Med Commun 2000; 21: 917-923.
30. Carril JM, Quirce R, Serrano J, Banzo I, Jimenez-Bonilla JF, Tabuenca O, Barquin RG. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med 1997; 38: 686-692.
31. Unal S, Menda Y, Adalet I, Boztepe H, Ozbey N, Alagol F, Cantez S. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. J Nucl Med 1998; 39: 1897-1902.
32. Haugen BR, Lin EC. Isotope imaging for metastatic thyroid cancer. Endocrinol Metab Clin North Am 2001; 30:469-492.
33. Schirrmeister H, Buck A, Guhlmann A, Reske SN. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid 2001; 11: 677-683.
34. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
35. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET in the management of patients with cancer. Semin Nucl Med 2002; 32: 35-46.
36. Higashi K, Matsunari I, Ueda Y, Ikeda R, Guo J, Oguchi M et al. Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med 2003; 17: 1-14.
37. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T et al. Early restaging positron emission tomography with (18) F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356-1363.
38. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 2003; 33: 148-162.
39. Ioanniclis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 2003; 44: 717-724.
40. Joensuu H, Ahonen A. Imaging of metastasis of thyroid carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl Med 1987; 28: 910-914.
41. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H and Mullerschauenburg W. Fluorine-18-FDG and Iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-1472.
42. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheichauer K, Dietlein M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547-1552.
43. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001; 42: 1464-1469
44. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 1342-1348.
45. Wong CO, Dworkin HJ. Role of FDG PET in metastatic thyroid cancer. J Nucl Med 1999; 40: 993-994.
46. Fridrich L, Messa C, Landoni C, Lucignani G, Moncayo R, Kendler D et al. Whole-body scintigraphy with 99Tcm-MIBI, 18F-FDG and 131I in patients with metastatic thyroid carcinoma. Nucl Med Commun 1997; 18: 3-9.
47. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999; 9: 797-804.
48. Wang W, Larson SM, Fazzan M, Tickoo SK, Kolbert K, Sgouros G et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000: 85: 1107-1113.
49. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42: 77-78.
50. Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M et al. Comparison of (18)F-FDG, (131)I-Na, and (201)TI in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001; 42: 414-419.
51. Boerner AR, Petrich T, Weckesser E, Fricke H, Hofmann M, Otto D et al. Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002; 29: 231-236.
52. Hung MC, Wu HS, Kao CH, Chen WK, Changlai SP. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res 2003; 29: 169-175.
53. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000; 41:1996-1998.